Financhill
Back

AN2 Therapeutics Quote, Financials, Valuation and Earnings

AN2 Therapeutics Price Quote

$1.35
+0.01 (+9.76%)
(Updated: November 23, 2024 at 5:25 AM ET)

AN2 Therapeutics Key Stats

Sell
48
AN2 Therapeutics (ANTX) is a Sell

Day range:
$1.26 - $1.42
52-week range:
$0.87 - $22.22
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0.46%

Volume:
1.2M
Avg. volume:
747.9K
1-year change:
-91.65%
Market cap:
$40M
Revenue:
$0
EPS:
$-2.04

How Much Does AN2 Therapeutics Make?

Data Unavailable

Is AN2 Therapeutics Growing As A Company?

Data Unavailable

AN2 Therapeutics Stock Price Performance

  • Did AN2 Therapeutics Stock Go Up Last Month?
    AN2 Therapeutics share price went up by 24.07% last month
  • Did ANTX's Share Price Rise Over The Last Year?
    ANTX share price fell by -91.65% over the past 1 year

What Is AN2 Therapeutics 52-Week High & Low?

AN2 Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy AN2 Therapeutics?

  • How Much Debt Does AN2 Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does AN2 Therapeutics Have?
    Cash and short term investments quarterly total is $93.4M
  • What Is AN2 Therapeutics’s Book Value Per Share?
    Book value per share is 2.94

Is AN2 Therapeutics Cash Flow Positive?

  • What Is ANTX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$61.1M
  • What Is AN2 Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $51K
  • What Is AN2 Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $61.9M

AN2 Therapeutics Return On Invested Capital

Data Unavailable

AN2 Therapeutics Earnings Date & Stock Price

AN2 Therapeutics Competitors

  • Who Are AN2 Therapeutics's Competitors?
    Below is a list of companies who compete with AN2 Therapeutics or are related in some way:
    • Arbutus Biopharma Corp (ABUS)
    • Biomarin Pharmaceutical Inc (BMRN)
    • Cidara Therapeutics Inc (CDTX)
    • FibroGen Inc (FGEN)
    • GlycoMimetics Inc (GLYC)

AN2 Therapeutics Dividend Yield

AN2 Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 8.97%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 3
Sell Recommendations: 1
Price Target: 2.67
Upside from Last Price: 99.01%

Major Shareholders

  • How many ANTX shares are owned by institutional investors?
    29.4M ANTX shares are owned by institutional investors
  • How many ANTX shares are owned by insiders?
    459.2K ANTX shares are owned by insiders